期刊
VACCINE
卷 27, 期 50, 页码 7080-7086出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.09.060
关键词
HIV vaccine; T helper epitopes; Phase I clinical trial
资金
- NIH/NCRR LICSF-CTSI [UL1 RR024131]
- HVTN of MAID
- DAIDS
A Phase I human vaccine trial of a novel polypeptide vaccine of HIV T helper epitopes (EP-1043) and a DNA vaccine of HIV CTL epitopes was conducted in 84 healthy adult volunteers. The vaccine immunogenicity was assessed by an intracellular cytokine staining assay for IL-2, IL-4, TNF-alpha and IFN-gamma. Sixty eight percent (32/47) of subjects had a positive CD4+ T response after receiving two vaccinations of the polypeptide vaccine. The responding CD4+ T cells made various combinations of IL-2, IL-4, IFN-gamma, and TNF-alpha. The study demonstrated that the EP-1043 vaccine is safe, well-tolerated, and immunogenic. (C) 2009 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据